Literature DB >> 27976670

Lyme borreliosis.

Allen C Steere1,2, Franc Strle3, Gary P Wormser4, Linden T Hu5, John A Branda6, Joppe W R Hovius7, Xin Li8, Paul S Mead9.   

Abstract

Lyme borreliosis is a tick-borne disease that predominantly occurs in temperate regions of the northern hemisphere and is primarily caused by the bacterium Borrelia burgdorferi in North America and Borrelia afzelii or Borrelia garinii in Europe and Asia. Infection usually begins with an expanding skin lesion, known as erythema migrans (referred to as stage 1), which, if untreated, can be followed by early disseminated infection, particularly neurological abnormalities (stage 2), and by late infection, especially arthritis in North America or acrodermatitis chronica atrophicans in Europe (stage 3). However, the disease can present with any of these manifestations. During infection, the bacteria migrate through the host tissues, adhere to certain cells and can evade immune clearance. Yet, these organisms are eventually killed by both innate and adaptive immune responses and most inflammatory manifestations of the infection resolve. Except for patients with erythema migrans, Lyme borreliosis is diagnosed based on a characteristic clinical constellation of signs and symptoms with serological confirmation of infection. All manifestations of the infection can usually be treated with appropriate antibiotic regimens, but the disease can be followed by post-infectious sequelae in some patients. Prevention of Lyme borreliosis primarily involves the avoidance of tick bites by personal protective measures.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27976670      PMCID: PMC5539539          DOI: 10.1038/nrdp.2016.90

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  216 in total

1.  Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.

Authors:  Linda K Bockenstedt; David G Gonzalez; Ann M Haberman; Alexia A Belperron
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

Review 2.  A critical appraisal of "chronic Lyme disease".

Authors:  Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

3.  Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia.

Authors:  F Strle; R B Nadelman; J Cimperman; J Nowakowski; R N Picken; I Schwartz; V Maraspin; M E Aguero-Rosenfeld; S Varde; S Lotric-Furlan; G P Wormser
Journal:  Ann Intern Med       Date:  1999-01-05       Impact factor: 25.391

4.  Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis.

Authors:  Klemen Strle; Junghee J Shin; Lisa J Glickstein; Allen C Steere
Journal:  Arthritis Rheum       Date:  2012-05

5.  Cefotaxime versus penicillin in the late stage of Lyme disease--prospective, randomized therapeutic study.

Authors:  D Hassler; L Zöller; M Haude; H D Hufnagel; F Heinrich; H G Sonntag
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

6.  Chronic symptoms are common in patients with neuroborreliosis -- a questionnaire follow-up study.

Authors:  M Vrethem; L Hellblom; M Widlund; M Ahl; O Danielsson; J Ernerudh; P Forsberg
Journal:  Acta Neurol Scand       Date:  2002-10       Impact factor: 3.209

7.  Epidemiological situation of Lyme borreliosis in germany: surveillance data from six Eastern German States, 2002 to 2006.

Authors:  Balazs Fülöp; Gabriele Poggensee
Journal:  Parasitol Res       Date:  2008-11-23       Impact factor: 2.289

8.  Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  J J Halperin; E D Shapiro; E Logigian; A L Belman; L Dotevall; G P Wormser; L Krupp; G Gronseth; C T Bever
Journal:  Neurology       Date:  2007-05-23       Impact factor: 9.910

9.  The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis.

Authors:  A R Pachner; A C Steere
Journal:  Neurology       Date:  1985-01       Impact factor: 9.910

10.  Acylated cholesteryl galactosides are specific antigens of borrelia causing lyme disease and frequently induce antibodies in late stages of disease.

Authors:  Gunthard Stübs; Volker Fingerle; Bettina Wilske; Ulf B Göbel; Ulrich Zähringer; Ralf R Schumann; Nicolas W J Schröder
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

View more
  178 in total

1.  Lyme neuroborreliosis and bird populations in northern Europe.

Authors:  Atle Mysterud; Dieter J A Heylen; Erik Matthysen; Aïda Lopez Garcia; Solveig Jore; Hildegunn Viljugrein
Journal:  Proc Biol Sci       Date:  2019-05-29       Impact factor: 5.349

2.  Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts.

Authors:  Ashley L Marcinkiewicz; Alan P Dupuis; Maxime Zamba-Campero; Nancy Nowak; Peter Kraiczy; Sanjay Ram; Laura D Kramer; Yi-Pin Lin
Journal:  Cell Microbiol       Date:  2019-01-07       Impact factor: 3.715

Review 3.  Lyme Neuroborreliosis: Clinical Outcomes, Controversy, Pathogenesis, and Polymicrobial Infections.

Authors:  Juan Carlos Garcia-Monco; Jorge L Benach
Journal:  Ann Neurol       Date:  2019-01       Impact factor: 10.422

4.  Identification of Lyme borreliae proteins promoting vertebrate host blood-specific spirochete survival in Ixodes scapularis nymphs using artificial feeding chambers.

Authors:  Thomas Hart; Xiuli Yang; Utpal Pal; Yi-Pin Lin
Journal:  Ticks Tick Borne Dis       Date:  2018-04-04       Impact factor: 3.744

5.  Correlation of Lyme Disease-Associated IgG4 Autoantibodies With Synovial Pathology in Antibiotic-Refractory Lyme Arthritis.

Authors:  Katherine B Sulka; Klemen Strle; Jameson T Crowley; Robert B Lochhead; Robert Anthony; Allen C Steere
Journal:  Arthritis Rheumatol       Date:  2018-09-24       Impact factor: 10.995

6.  mRNA transcript distribution bias between Borrelia burgdorferi bacteria and their outer membrane vesicles.

Authors:  Anjali Malge; Vikas Ghai; Panga Jaipal Reddy; David Baxter; Taek-Kyun Kim; Robert L Moritz; Kai Wang
Journal:  FEMS Microbiol Lett       Date:  2018-07-01       Impact factor: 2.742

7.  A Fully Automated Multiplex Assay for Diagnosis of Lyme Disease with High Specificity and Improved Early Sensitivity.

Authors:  Johnnie B Hahm; John W Breneman; Jing Liu; Svetlana Rabkina; Weiming Zheng; Shuxia Zhou; Roger P Walker; Ravi Kaul
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

8.  Suspicious index in Lyme carditis: Systematic review and proposed new risk score.

Authors:  Georgia Besant; Douglas Wan; Cynthia Yeung; Crystal Blakely; Pamela Branscombe; Laiden Suarez-Fuster; Damian Redfearn; Christopher Simpson; Hoshiar Abdollah; Benedict Glover; Adrian Baranchuk
Journal:  Clin Cardiol       Date:  2018-11-26       Impact factor: 2.882

Review 9.  Clinical spectrum of Lyme disease.

Authors:  Jesus Alberto Cardenas-de la Garza; Estephania De la Cruz-Valadez; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-19       Impact factor: 3.267

Review 10.  Borrelia burgdorferi glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease.

Authors:  Yi-Pin Lin; Lingyun Li; Fuming Zhang; Robert J Linhardt
Journal:  Microbiology       Date:  2017-11-08       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.